Log in

NASDAQ:MYOKMyokardia Stock Price, Forecast & News

$52.92
+2.77 (+5.52 %)
(As of 04/10/2020 07:48 AM ET)
Add
Compare
Today's Range
$50.45
Now: $52.92
$53.76
50-Day Range
$43.50
MA: $55.47
$70.71
52-Week Range
$42.65
Now: $52.92
$78.28
Volume498,933 shs
Average Volume583,059 shs
Market Capitalization$2.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.1
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Read More
Myokardia logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.56 million
Book Value$8.79 per share

Profitability

Net Income$-276,210,000.00

Miscellaneous

Employees165
Market Cap$2.47 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.


Myokardia (NASDAQ:MYOK) Frequently Asked Questions

How has Myokardia's stock been impacted by COVID-19 (Coronavirus)?

Myokardia's stock was trading at $55.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MYOK shares have decreased by 5.3% and is now trading at $52.92. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Myokardia?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myokardia in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Myokardia.

When is Myokardia's next earnings date?

Myokardia is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Myokardia.

How were Myokardia's earnings last quarter?

Myokardia Inc (NASDAQ:MYOK) released its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.41) by $0.07. View Myokardia's earnings history.

What price target have analysts set for MYOK?

11 analysts have issued 12-month price objectives for Myokardia's stock. Their forecasts range from $76.00 to $104.00. On average, they anticipate Myokardia's stock price to reach $89.10 in the next twelve months. This suggests a possible upside of 68.4% from the stock's current price. View analysts' price targets for Myokardia.

What are Wall Street analysts saying about Myokardia stock?

Here are some recent quotes from research analysts about Myokardia stock:
  • 1. According to Zacks Investment Research, "MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy, DCM-1, treats heritable dilated cardiomyopathy by restoring normal contractility in the diseased DCM heart, HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients and LUS-1, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart, which are in different clinical trial. MyoKardia, Inc. is headquartered in San Francisco, California. " (3/4/2020)
  • 2. Cantor Fitzgerald analysts commented, ": 12-month price target of $90. MYOK reported earnings this evening and an increased cash balance of ~ $630M after raising capital in 1Q19. We think that the company is well-capitalized to take advantage of its research discovery platform. One key update today was that the MAVERICK study (non-obstructive) has completed enrollment. We expect that this study will be an important catalyst for the company in 4Q19; we still think that current share levels do not reflect credit for non-obstructive. We still see additional pipeline catalysts beyond mavacamten in obstructive in 2H 2019 that keep us very positive on shares at the current level." (5/9/2019)

Has Myokardia been receiving favorable news coverage?

Press coverage about MYOK stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Myokardia earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutMyokardia.

Who are some of Myokardia's key competitors?

What other stocks do shareholders of Myokardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myokardia investors own include Micron Technology (MU), NVIDIA (NVDA), CVS Health (CVS), AT&T (T), Exelixis (EXEL), Johnson & Johnson (JNJ), Raytheon (RTN), Cisco Systems (CSCO), AbbVie (ABBV) and Alibaba Group (BABA).

Who are Myokardia's key executives?

Myokardia's management team includes the following people:
  • Mr. Tassos Anastasios Gianakakos, Pres, CEO & Director (Age 46)
  • Dr. Robert S. McDowell, Chief Scientific Officer (Age 61)
  • Dr. June Lee, Exec. VP & Chief Devel. Officer (Age 53)
  • Dr. Charles J. Homcy, Advisor (Age 71)
  • Dr. Eric J. Topol, Advisor (Age 65)

What is Myokardia's stock symbol?

Myokardia trades on the NASDAQ under the ticker symbol "MYOK."

How do I buy shares of Myokardia?

Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Myokardia's stock price today?

One share of MYOK stock can currently be purchased for approximately $52.92.

How big of a company is Myokardia?

Myokardia has a market capitalization of $2.47 billion and generates $33.56 million in revenue each year. The biotechnology company earns $-276,210,000.00 in net income (profit) each year or ($4.38) on an earnings per share basis. Myokardia employs 165 workers across the globe. View additional information about Myokardia.

What is Myokardia's official website?

The official website for Myokardia is http://www.myokardia.com/.

How can I contact Myokardia?

Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel